Mechanism: GH Axis
AOD-9604 vs Tesamorelin: Mechanism Comparison
Two very different mechanisms with the same broad goal. AOD-9604 is a GH fragment marketed for lipolysis without GH observed effects in study models. Tesamorelin is a GHRH analogue with strong visceral fat data.
Side-by-side comparison
| Attribute | AOD-9604 | Tesamorelin |
|---|---|---|
| Mechanism | GH fragment 176 to 191, lipolytic without GH effects | GHRH analogue raising endogenous GH |
| Effect on IGF-1 | None | Significant rise |
| Strongest human data | Phase 2b, modest metabolic research vs placebo | Phase 3, 15 to 18 percent visceral fat reduction |
| tolerability profile in study models | Minimal | Injection site, fluid retention, glucose changes |
| Typical research dose | 250 to 500 mcg daily | 2 mg daily |
Key differences
- ·AOD-9604 acts on beta-3 adrenergic pathway, does not raise systemic GH or IGF-1
- ·Tesamorelin raises GH and IGF-1 with downstream lipolytic effects
- ·Human AOD-9604 metabolic research trials have shown modest or null effects
- ·Tesamorelin has reproducible visceral fat reduction in phase 3 trials
Research summary
AOD-9604 phase 2b trials by Metabolic Pharmaceuticals (2007) failed to reach primary metabolic research endpoint vs placebo. Tesamorelin Falutz et al. (2007) showed clear visceral fat reduction. For evidence-led lipolysis research, tesamorelin is the stronger choice.